Telix Pharmaceuticals Limited Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019
Telix Pharmaceuticals Limited (TLPPF) had Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 of 8.58 AUD/shares as of 2024-12-31, per its 20-F filed 2025-02-24.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 · last filed 2025-02-24
- 2024-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 8.58 AUD/shares.
- 2023-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 5.59 AUD/shares.
- 2022-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 3.62 AUD/shares.
| Period end | Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 |
|---|---|
| 2024-12-31 | 8.58 AUD/shares 20-F · filed 2025-02-24 |
| 2023-12-31 | 5.59 AUD/shares 20-F · filed 2025-02-24 |
| 2022-12-31 | 3.62 AUD/shares 20-F · filed 2025-02-24 |